Search results
Results From The WOW.Com Content Network
Estrogen dosages for menopausal hormone therapy; Route/form Estrogen Low Standard High Oral: Estradiol: 0.5–1 mg/day: 1–2 mg/day: 2–4 mg/day Estradiol valerate: 0.5–1 mg/day: 1–2 mg/day
Plasma estrogen levels after a single dose of conjugated estrogens by different routes ; Route Dose Time E2 (↑Δ) E1 (↑Δ) Ratio Ref Oral 0.3 mg 0.625 mg 1.25 mg 1.25 mg 2.5 mg: 6 hours
[8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10]
epoetin beta: NeoRecormon, made by Hoffmann–La Roche; Recormon; Methoxy polyethylene glycol-epoetin beta (Mircera) by Roche [20] epoetin delta: Dynepo trademark name for an erythropoiesis stimulating protein, by Shire plc [21] epoetin omega: Epomax; epoetin zeta (biosimilar forms for epoetin alpha): Silapo (STADA Arzneimittel AG) [22]
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).
So, the maintenance dose of foosporin is 100 milligrams (100 mg) per day—just enough to offset the amount cleared. Suppose a patient just started taking 100 mg of foosporin every day. On the first day, they'd have 100 mg in their system; their body would clear 10 mg, leaving 90 mg.
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
According to Roche, the product has the longest half-life of all FDA-approved erythropoiesis-stimulating agents (ESAs): up to 6 times longer than darbepoetin alfa and up to 20 times longer than epoetin. CERAs thus promise both lower dosing—significant owing to the high inherent cost of manufacturing recombinant protein drugs—and less ...